Genmab A/S (GMAB)

GMAB trades at $33.56, 11.9% above the near-term max pain of $30 expiring Oct 17, 2025 (12 days). Expect downward pressure as dealers benefit from price declining toward max pain. Max pain is rising across expirations ($15-$30), reflecting growing call interest at higher strikes. High dispersion in max pain levels suggests competing forces and potential volatility.

Max pain for GMAB shows an upward trend from 15 to 30, suggesting bullish positioning in longer-dated options. The 69% spread signals divergent expectations across timeframes. Most levels below 33.56 may cap rallies. Weekly expirations influence price 2-3 days before expiry; monthlies throughout their final week.